Mark A. Schlossberg
Net Worth

Last updated:

What is Mark A. Schlossberg net worth?

The estimated net worth of Mr. Mark A. Schlossberg is at least $8,836,457 as of 15 Mar 2022. He owns shares worth $4,000,856 as insider, has earned $1,710,301 from insider trading and has received compensation worth at least $3,125,300 in Cytokinetics, Incorporated.

What is the salary of Mark A. Schlossberg?

Mr. Mark A. Schlossberg salary is $625,060 per year as Senior Vice President of Legal, Gen. Counsel & Sec. in Cytokinetics, Incorporated.

How old is Mark A. Schlossberg?

Mr. Mark A. Schlossberg is 64 years old, born in 1961.

What stocks does Mark A. Schlossberg currently own?

As insider, Mr. Mark A. Schlossberg owns shares in one company:

Company Title Shares Price per share Total value
Cytokinetics, Incorporated (CYTK) Senior Vice President of Legal, Gen. Counsel & Sec. 103,408 $38.69 $4,000,856

What does Cytokinetics, Incorporated do?

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK logo
CYTK
Cytokinetics, Incorporated
$38.69

Mark A. Schlossberg insider trading

Cytokinetics, Incorporated

Mr. Mark A. Schlossberg has made 4 insider trades between 2020-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 30,818 units of CYTK stock on 15 Mar 2022. As of 15 Mar 2022 he still owns at least 103,408 units of CYTK stock.

Transaction Date Security Shares Price per share Total value Source
Option
Incentive Stock Option (right to buy) 4,803 $14.4 $69,163
Option
Incentive Stock Option (right to buy) 30,818 $7.03 $216,651
Option
Non-Qualified Stock Option (right to buy) 25,196 $14.4 $362,822
Option
Common Stock 30,818 $7.03 $216,651
Option
Common Stock 4,803 $14.4 $69,163
Option
Common Stock 25,196 $14.4 $362,822
Sale
Common Stock 25,196 $33.96 $855,732
Option
Common Stock 19,979 $7.03 $140,452
Option
Non-Qualified Stock Option (right to buy) 19,979 $7.03 $140,452
Sale
Common Stock 19,979 $35.74 $713,970
Option
Common Stock 10,000 $7.03 $70,300
Sale
Common Stock 10,000 $7.03 $70,300
Option
Non-Qualified Stock Option (right to buy) 10,000 $7.03 $70,300
Option
Non-Qualified Stock Option (right to buy) 10,000 $7.03 $70,300
Option
Common Stock 10,000 $7.03 $70,300
Sale
Common Stock 10,000 $7.03 $70,300

Cytokinetics, Incorporated key executives

Cytokinetics, Incorporated executives and other stock owners filed with the SEC: